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Abstract
Background: The Breathlessness Intervention Service is a novel service for patients with intractable breathlessness
regardless of aetiology. It is being evaluated using the Medical Research Council's framework for the evaluation of
complex interventions. This paper describes the feasibility results of Phase II: a single-blinded fast-track pragmatic
randomised controlled trial.
Methods: A single-blinded fast-track pragmatic randomised controlled trial was conducted for patients with chronic
obstructive pulmonary disease referred to the service. Patients were randomised to either receive the intervention
immediately for an eight-week period, or receive the intervention after an eight-week period on a waiting list during
which time they received standard care. Outcomes examined included: response rates to the trial; response rates to the
individual questionnaires and items; comments relating to the trial functioning made during interviews with patients,
carers, referrers and service providers; and, researcher fieldwork notes.
Results: 16 of the 20 eligible patients agreed to participate in a recruitment visit (16/20); 14 respondents went on to
complete a recruitment visit/baseline interview. The majority of those who completed a recruitment visit/baseline
interview completed the RCT protocol (13/14); 12 of their carers were recruited and completed the protocol. An
unblinding rate of 6/25 respondents (patients and carers) was identified. Missing data were minimal and only one patient
was lost to follow up. The fast-track trial methodology proved feasible and acceptable. Two of the baseline/outcome
measures proved unsuitable: the WHO performance scale and the Schedule for the Evaluation of Individual Quality of
Life-Direct Weighting (SEIQoL-DW).
Conclusion: This study adds to the evidence that fast-track randomised controlled trials are feasible and acceptable in
evaluations of palliative care interventions for patients with non-malignant conditions. Reasonable response rates and low
attrition rates were achieved. Further, with adequate preparation of the research and randomisation teams, clinicians,
and responders, and effective liaison with the clinicians, single-blinding proved possible. Methods were identified to
reduce unblinding through careful attention to the type of data collected at unblinded measurement points; the content
of interviews should be carefully considered when designing blinded-trial protocols.
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Background
Intractable breathlessness is common in advanced dis-
ease, both malignant and non-malignant. In chronic
obstructive pulmonary disease (COPD) and heart failure
it is nearly universal by the time of death, its prevalence
reaching 90–95% and 60–88% respectively in the
advanced stages [1]. Recent advances in the palliation of
breathlessness include non-pharmacological intervention
services to reduce or contain the severity of the sensation.
Formally evaluated services have had positive outcomes
in terms of reduction in distress caused by breathlessness,
increased functioning and quality of life [2-5], however
these services focused solely on patients with malignant
disease and their evaluations were methodologically lim-
ited (e.g. only two were randomised controlled trials
(RCTs) and published outcomes were limited to patient
outcomes only). These were complex interventions which
are notoriously difficult to evaluate [6].
The Medical Research Council's Framework for the Devel-
opment and Evaluation of RCT for Complex Interventions
to Improve Health [6] was developed to combat the
unique challenge of evaluating complex interventions by
building a continuum of increasing evidence to support
the effective development of complex interventions
through robust methodology. It was described as the cur-
rent method of choice for assessing complex interventions
for breathlessness by the 2005 Medical Research Council
(MRC) Clinical Trials Unit/Cicely Saunders Foundation
'Improving Research Methodology in Breathlessness'
meeting [7].
The Breathlessness Intervention Service (BIS) Service at
Addenbrooke's NHS Trust is being evaluated using the
MRC framework [6]. BIS aims to manage the symptom of
intractable breathlessness in patients with disease of any
aetiology (malignant and non-malignant) using a rehabil-
itative approach. Interventions include evidence-based
non-pharmacological interventions (psychological, social
and physical), palliative care input (e.g. end of life issues,
psychosocial issues, family concerns) and pharmacologi-
cal review. Thus BIS seeks to enhance the self-manage-
ment of breathlessness. Uniquely, care is flexibly located
preferentially in patients' own homes, or in a clinic if
more appropriate. Referrals come from medical special-
ists, GPs and allied health professionals (with medical
consent). At Phase II BIS was staffed by a clinical specialist
physiotherapist and palliative care consultant.
The MRC framework has recommended RCTs as the gold
standard for evaluating services [6], however conducting
RCTs within palliative care is challenging because of diffi-
culties with recruitment, due to acceptability, and attri-
tion, associated with increasing morbidity and death [8].
Following the experience of Higginson et al (2006 &
2008) [9,10], a fast-track RCT model was selected to
address these difficulties. This design has previously been
attempted in palliative care by McWhinney et al (1994)
[11] to evaluate a palliative care home support team but
this single-blinded trial failed to recruit an adequate sam-
ple size due to problems with attrition and inaccurate
prognostication; it is unclear what diagnoses the interven-
tion was targeted at, but it was likely to have been patients
with malignancies. The recent successful palliative care
fast-track RCT by Higginson et al (2006 & 2008) evaluated
a palliative care service for people affected by multiple
sclerosis, however the authors made no attempt at blind-
ing [9,10]. Hart et al (2008) describe the 'impossibility' of
double-blinding in experience-based trials, but stress the
importance of single-blinding the investigator where pos-
sible [12]. Thus the Phase II study reported here sought to
test the feasibility of single-blinding in a fast-track prag-
matic RCT of BIS versus standard care for patients with a
different non-malignant disease (COPD) and their infor-
mal carers. Results of the earlier phases of the develop-
ment and evaluation of BIS have been published
elsewhere [13,14].
Method
Sample
Although the BIS accepts referrals for patients with both
malignant and non-malignant conditions, COPD patients
make up the largest diagnostic group of referrals. In addi-
tion, a body of work (cited earlier) has begun to address
the role of such interventions (albeit only in a clinic set-
ting) in patients with malignancies. Therefore this Phase
II trial focused on a homogeneous cohort of COPD
patients, although BIS continued to deliver the interven-
tion to patients with other diagnoses such as cancer and
heart failure outside of the trial.
RCT design
A single-blinded fast-track pragmatic RCT design was
used. Patients were randomised either to a fast-track
group (FT), where they received the intervention immedi-
ately, or the control condition (the waiting list group;
WL), where they received the intervention after an eight-
week period on a waiting list during which time they
received standard care.
Definition of intervention and standard care
Table 1 defines the intervention that BIS provided, in
terms of a minimum set of core interventions for non-
malignant patients at Phase II.
The control group received standard care for an eight-
week period before receiving BIS. Our definition of stand-
ard care, in the context of this Phase II RCT, was: specialist
outpatient appointments in secondary care (e.g. respira-BMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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Table 1: Service model for the Breathlessness Intervention Service (BIS) for non-malignant patients at Phase II RCT (model date: 15/
12/06: since revised)
Target patient group: Refractory dyspnoea – chronic breathlessness which is medically 
optimally managed
Referral: Post, fax, electronic
Assessment lead: Clinical Specialist Physiotherapist
BIS team: ❑ Clinical Specialist Physiotherapist: expert in three different disease 
groups (cancer, heart failure, COPD), conducts highly specialised 
assessment, works off-site and on-site.
❑ Palliative Medical Consultant
Medical assessment: May be required
Average no. of home visits: 3
Average no. of telephone contacts: 3
Ratio of face-to-face to telephone: 1:1
Average length of service contact: 6–8 weeks
Outcome measures collected at first assessment: ❑ modified Borg [19] at rest, self-reported, on exertion completion 
of exercise test
❑ anxiety due to breathlessness at rest, self reported, on exertion & 
on completion of exercise test
❑ physiological measures e.g. oxygen saturation, heart rate & 
respiratory rate
Non-pharmacological interventions: 1st stage of intervention
Pharmacological interventions: 2nd stage of intervention
1st stage interventions (selection & application as clinically indicated, 
majority used):
❑ explanation & reassurance
❑ anxiety management
❑ psychological support
❑ hand-held fan
❑ information fact sheets
❑ emergency plan
❑ positioning to reduce work of breathing (rest, recovery & activity)
❑ breathing control
❑ education to patient, carer & health care generalists
❑ pacing & lifestyle adjustment
❑ individualised exercise plan
❑ relaxation & visualisation
❑ airway clearance techniques
❑ advice regarding nutrition & hydration
❑ support to family & patient to utilise education & self-support 
programmes
❑ sleep hygiene
❑ smoking cessation prompt
❑ brief cognitive therapy
❑ pharmacological reviewBMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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tory) that may include specialist nurse input, and primary
care services.
Single-blinding
Various placebos were considered but found to be
unworkable for the clinicians and unbelievable as 'inter-
ventions' to the patient and carer populations. It was also
considered possibly unethical for the clinicians given that
BIS was using evidence-based interventions. Further, it
was impossible to blind the clinicians to the group to
which patients were allocated as the providers delivered
the intervention to both groups and had necessary access
to their referral histories (i.e. dates of referral). In prag-
matic trials of services, blinding patients and clinicians is
nearly always impossible [8,15]. For this Phase II trial an
attempt was made to blind the researcher to the allocation
of respondents until the end of the intervention period
(week 8).
This was achieved by the researcher conducting the
recruitment to the study and collecting baseline measures,
but then passing the process of randomisation and report-
ing of allocation over to a third party (Addenbrooke's clin-
ical trials' team). Patients were randomised to the fast-
track group (FT) or the waiting list group (WL) by the clin-
ical trials' team sequentially opening sealed opaque num-
bered envelopes containing the random group allocation
previously generated by a computer programme at King's
College London (KCL). The envelopes were set up by an
administrator at KCL not associated with the study.
Patients were then informed of the outcome of randomi-
sation by the clinical trials' team, by telephone. BIS was
then notified of the outcome of randomisation by the
clinical trials' team (by telephone and secure email) in
order that the service could book the first appointment
with the patient in-line with the study protocol. The
researcher was then notified that randomisation had
occurred, and that the patient and service had been
informed, but not the outcome of the randomisation. The
purpose and need for single blinding was explained to
patients and carers at the recruitment visit and they were
reminded at the start of each subsequent blinded inter-
view to try not to let the researcher know their group allo-
cation. In addition, all data were handled using study
identity numbers; group allocation identifiers were only
added at the analysis stage.
Data collected from the waiting list group once they were
in receipt of BIS (after their period on the waiting list
when their group allocation was blinded to the
researcher) was treated as before/after data and not RCT
data. This allowed for the collection of qualitative data at
the midpoint of using the service for the waiting list group
as the researcher was no longer blinded to their group
allocation, nor was she required to be at this stage.
Measurement points
Quantitative and qualitative data were collected by inter-
view for all respondents at baseline (t1), prior to randomi-
sation. A flow chart depicting the follow up measurement
points is given in Figure 1.
Sample size
As this was a feasibility study, comparative analysis was
not our primary objective thus adequate powering of the
2nd stage interventions (choice dependent on outcome of first stage 
interventions):
❑ further pharmacological review e.g. low dose opioids, anti-
depressants, anxiolytics
❑ referral to specialist services (see below)
❑ referral for long term oxygen therapy (LTOT) or short burst 
oxygen therapy (SBOT) assessment
Other symptom management: May be required
Documentation: ❑ individualised patient plan
❑ discharge summary to referrer with copies to GP, specialist 
services the patient was already in contact with (e.g. respiratory 
physicians), other involved health care professionals 
(e.g. district nurses, nursing home care staff)
Referrals: ❑ Pulmonary rehabilitation
❑ Specialist dietetic
❑ OT advice
❑ Specialist psychological services
❑ Hospice day services
❑ other specialist assessment
❑ (n.b. these services usually have a wait time)
Table 1: Service model for the Breathlessness Intervention Service (BIS) for non-malignant patients at Phase II RCT (model date: 15/
12/06: since revised) (Continued)BMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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Flow chart depicting the follow up measurement points Figure 1
Flow chart depicting the follow up measurement points
WEEK 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Baseline interview t1 
(n=16)
Withdrawn by 
researcher (significant 
deterioration between 
agreeing to recruitment 
visit and visit) (n=2)
Eligible patients 
(n=20)
Starts to receive BIS (n=7) 
Mid-intervention interview t2 
(n=7)
End of intervention interview  
t3 (n=7)
Mid-waiting interview t2 (n=7)
End of waiting interview t3 n=6)
Waiting list group starts to 
receive BIS (n=6) 
Mid-intervention interview t4 
(n=6)
End of intervention interview 
t5 (n=6)
Agreed to recruitment 
visit n=16 
Fast-track group  Waiting list group
Receives standard care (n=7) 
Taken off 
study n=1 
(died)
Referrer interview 
Referrer interview
= interventionBMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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Table 2: Patient and carer baseline and outcome measures for BIS Phase II RCT
Baseline characteristic/outcome Instrument/measure
PATIENT
Patient breathlessness Modified Borg [19] at rest and on exertion & identification of activity that makes 
breathlessness worst
Patient breathlessness at best/worst Visual Analogue Scale (VAS) [7]
Patient functional ability WHO performance scale [16]
Patient social functioning No. of times patient goes out of the house (average for last month)
Patient quality of life SEIQoL-DW [17]
Patient satisfaction with the service Qualitative (t1 – expectations of the BIS; t3/t5 – useful aspects of the service)
Patient critical incidents data Qualitative 
(e.g. identification of examples of difficulty getting help/medication/advice needed)
Patient anxiety Hospital Anxiety and Depression Scale [20]
Patient distress due to breathlessness Visual Analogue Scale for distress caused by breathlessness [7]
Patient mastery of breathlessness Mastery items from Chronic Respiratory Questionnaire [18]1
Patient use of other services Service use questions
CARER
Carer quality of life SEIQoL-DW [17]
Carer satisfaction with the service Qualitative (t1 – expectations of the BIS; t3/t5 – useful aspects of the service)
Carer critical incidents data Qualitative 
(e.g. identification of examples of difficulty getting help/medication/advice needed)
Carer anxiety Hospital Anxiety and Depression Scale [20]
Carer's assessment of patient's breathlessness Modified Borg [19] at rest and on exertion & identification of activity that makes 
breathlessness worst
Carer's assessment of patient's breathlessness at best/worst VAS adapted for carer
Carer distress due to patient's breathlessness VAS adapted for carer – distress caused to carer by patient's breathlessness
Carer's assessment of patient's use of services Service use questions
Carer's social functioning No. of times carer goes out of the house (average for last month)
Caregiver burden Burden Interview [21]
Caregiver Appraisal Scale [22]
1Confirmation that it was valid to use these items in isolation of the whole Chronic Respiratory Questionnaire was received from its developer, 
Gordon Guyatt (email communication, 2005).BMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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trial was not required. Based on clinical and research expe-
rience and data published from other studies we aimed to
recruit a maximum of 28 patients to the trial. Phase II
would then provide the data, at this time lacking, to
inform the power calculations for a Phase III RCT.
Baseline and outcome measures
Baseline characteristics and outcomes included patients'
breathlessness, patient and carer distress due to breath-
lessness, patient mastery of breathlessness, patient and
carer quality of life, patient and carer anxiety, other service
use, caregiver burden, and patient and carer expectations
of and satisfaction with the service. Table 2 outlines the
baseline and outcome measures selected following a
review of the literature [7,16-22]. The resulting interview
schedule was both quantitative and qualitative at each
measurement point except t2; thus this was a mixed meth-
ods RCT.
Despite not powering the trial, a primary outcome meas-
ure was identified in order that the results could inform
the sample size calculations for Phase III. The primary
outcome measure was 'distress due to breathlessness'
measured using a Visual Analogue Scale (VAS; 0–10 cm);
a difference between the baseline and follow up measure-
ments of 1 cm on this scale could be regarded as clinically
significant for patients with intractable breathlessness
[23].
Inclusion and exclusion criteria
Table 3 shows the inclusion and exclusion criteria. These
criteria were established in order to ensure the representa-
tiveness of the study sample to the population who would
receive the BIS outside of the trial.
Data collection
Recruitment, randomisation and baseline interviews were
conducted over a ten-month period between late March
2006 and early January 2007; the final patient interview
was conducted in March 2007. All measurement points
were audio-taped with respondents' permission and were
conducted by experienced researchers (MF and GE). All
patient interviews were conducted in their own homes;
interviews with carers were conducted in their own
homes, at their place of work or at their patient's home
according to preference. Wherever possible, patients and
carers were interviewed separately. Careful attention was
paid to need, in terms of fatigue.
Data management
Quantitative data (e.g. structured questionnaires) were
entered into SPSS. Interviews t1, t3 and t5 were tran-
scribed by an independent transcription company,
checked for accuracy and anonymised. Transcripts were
then imported into NUD*IST software to enable storage
and organisation of the data for analysis.
Approvals and trial registration
Ethics approval was obtained from the Cambridge LREC
and R&D approval from Addenbrooke's R&D and the rel-
evant local Primary Care Trusts (REC reference no. 05/
Q0108/471). The trial was registered with ClinicalTri-
als.gov (NCT00711438).
Data analysis
In order to examine the feasibility of the trial methodol-
ogy, the following were examined: response rates to the
trial; response rates to the individual questionnaires and
items; comments relating to the trial functioning made
Table 3: Inclusion & Exclusion criteria for entry to BIS Phase II RCT
Inclusion criteria
Patients i) Appropriate referral to the BIS
ii) Diagnosis of COPD/COAD
iii) Aged 18 years or over
iv) Any patient who does not meet any of the exclusion criteria
Carers i) The informal carers of patients specified above, who can be significant others, relatives, friends or neighbours
ii) Aged 18 years or over
iii) Any carer who does not meet the exclusion criteria
Exclusion criteria
Patients/carers i) Any patient/carer unable to give informed consent
ii) Any patient living outside of Cambridgeshire PCT, West Essex PCT, East & North Hertfordshire PCT, or Suffolk PCT
iii) Any patient who has previously had access to BIS
iv) Any patient/carer who is demented or confused
v) Any patient/carer with learning difficulties
vi) Any patient/carer from other vulnerable groups (e.g. head injury, severe trauma, and mental illness)BMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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during interviews with patients, carers, referrers and BIS
providers; and, researcher fieldwork notes.
Results
Our original sample size was 28 patients. As the Phase II
exploratory RCT progressed it became clear that: 1) BIS for
patients with COPD could be conducted over a shorter
time period than eight-weeks; 2) BIS needed to be evalu-
ated across the full disease spectrum it served (malignant
as well as non-malignant diseases other than COPD); 3)
the service model for BIS was different for malignant and
non-malignant conditions due to the differing disease tra-
jectories, such that separate RCT protocols for evaluation
of BIS for malignant and non-malignant conditions
would be required; 4) some of the outcome measures
were unsuitable or could be improved upon; 5) there
would be difficulty maintaining clinical equipoise for
COPD patients for a Phase III definitive RCT if the explor-
atory RCT continued; 6) assessment of cost effectiveness
was warranted. Thus Phase II was discontinued 10
months into the RCT. Further details on these points fol-
low in this and the following discussion sections.
Table 4: BIS Phase II RCT response rates
ID No. Agreed to recruitment/baseline visit? Recruitment visit completed? Reason for non-response
001 Yes Yes
002 No n/a Moving house
003 Yes Yes
004 Yes Yes
005 Yes Yes
006 Yes Yes
007 Yes No – withdrawn by researcher & referred 
straight to BIS
Significant deterioration between agreeing & 
baseline interview (t1)
008 No n/a Admitted to ITU – too ill on discharge
009 Yes Yes
010 No n/a None given
011 Yes Yes
012 No n/a Too ill (nursing home resident)
013 Yes Yes
014 Yes Yes (but carer unobtainable)
015 Yes (but died on waiting list; carer refused) Yes (but died on waiting list; carer refused)
016 Yes Yes
017 Yes Yes
018 Yes No – withdrawn by researcher & referred 
straight to BIS
Admission & significant deterioration 
between agreeing & baseline interview (t1)
019 Yes Yes
020 Yes YesBMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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At the time of discontinuation, 20 patients had met the
inclusion criteria for Phase II. No patients with COPD
referred to BIS during the study period were excluded.
Table 4 shows the response rates of the 20 eligible
patients.
Sixteen of the 20 patients invited to participate agreed to
a recruitment visit, 14 completed the recruitment visit and
13 went on to complete the RCT protocol. Two patients
were withdrawn by the researcher between agreeing to the
recruitment visit and the conduct of the recruitment visit
(one following research-carer phone discussions between
the two events, and one on arrival of the researcher at the
recruitment visit). This occurred prior to informed con-
senting and randomisation, and was due to significant
deterioration in the patients' health: one was admitted to
hospital with an acute exacerbation and the other was
clearly entering the terminal stage and would not have
been able to participate (the carer had called the GP just
prior to the researcher's arrival).
No difficulties were reported by the third party randomi-
sation team (Addenbrooke's Clinical Trials Team) either
in terms of managing the randomisation process, contact-
ing patients, contacting BIS or contacting the researcher.
Table 5 shows the outcome of randomisation.
Seven patients were randomised to the fast-track (FT)
group and seven to the waiting list (WL) group. One
patient died whilst on the waiting list so reducing the final
WL sample size to six: this was the only patient lost to
attrition. Figure 2 provides a CONSORT flow chart sum-
marising the numbers for study enrolment, randomisa-
tion, allocation, follow up and analysis. Carers were
identified for all 13 respondents however one could not
be contacted due to a house move; 12 therefore partici-
pated and completed the carers' protocol.
As described earlier, the protocol was designed in order
that the researcher could remain blinded to group alloca-
tion until the qualitative questions at t3 (week 8). In this
Table 5: BIS Phase II RCT randomisation outcome
Recruitment/randomisation 
order
Recruitment/ID no. Fast-Track group Waiting List group Unblinded early?
1 01 1 By patient at t2
20 3 1 N o
30 5 2 N o
4 04 2 By patient
5 06 3 By patient at t3 (early)
60 9 3 N o
71 1 4 N o
81 3 4 N o
9 15 (died pre t3) (X) No
10 14 5 By patient on phone pre t3
11 16 6 By patient at t2
12 17 5 By carer at t1 (conducted post-patient's 
t1 and randomisation) *
13 19 6 No
14 20 7 No
Total 7 6 6/13
* unblinded to wrong groupBMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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CONSORT flow chart summarising the numbers for study enrolment, randomisation, allocation, follow up and analysis Figure 2
CONSORT flow chart summarising the numbers for study enrolment, randomisation, allocation, follow up and analysis
Allocated to intervention 
(n=7)
Received allocated 
intervention (n=7) 
Did not receive allocated 
intervention (n=0) 
Allocated to control (n=7) 
Received allocated 
control (n=7) 
Did not receive allocated 
control (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention 
(n=0)
Lost to follow-up (n=1) 
(Reason: died) 
Discontinued allocated 
control (n=0)
Analysed (n=7) 
Excluded analysis (n=0)
Follow-up
(n=13)
Allocation
(n=14)
Analysed (n=6) 
Excluded analysis (n=0)
Assessed for eligibility 
(n=20)
Enrolment 
(n=16)
Refused recruitment visit 
(t1) (n=4) 
Reasons: moving house, 
too ill, none given 
Significant deterioration 
between agreeing to 
recruitment visit (t1) and 
t1 – withdrawn by 
researcher (n=2)
Randomised 
(n=14)
Analysis 
(n=13)BMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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pragmatic trial five of the 13 patients and one of the 12
carers who completed the study unblinded the researcher
prior to this point (see Table 5). One of these unblindings
(a carer) was to the wrong group i.e. the carer implied that
their patient was in the fast-track group (receiving BIS)
when in fact they were in the waiting list group and the
patient had not yet seen BIS. Including this latter unblind-
ing, there was therefore a 6 out of 25 respondents
unblinding rate (base number consists of 13 patients and
12 carers). All unblindings appeared to be accidental
rather than deliberate, and unblinders did not appear to
be aware that they had unblinded themselves. Most
unblindings took the form of mentioning a visit or con-
tact by the BIS physiotherapist.
Sample characteristics
The age range of responding patients was 53–80 years,
with a median of 69 years. The majority of patients were
male (8/13). Their most recent FEV1 ranged from 0.68–
1.28 litres/min and % predicted ranged from 12.6–
28.9%. The age range of responding carers was 29–76
years, with a median of 57 years, and the majority of carers
were female (9/12).
Table 6: Obtained and missing data measurement points for patients and carers in BIS Phase II RCT
ID No. Interview no.
t1 t2 t3 t4 t5
Pt Carer Pt Carer Pt Carer Pt Carer Pt Carer
001 D D D D D D n/a n/a n/a n/a
0 0 3 D DD DD DD DD D
0 0 4 D DD DD DD I D I D D
005 D D D D D D n/a n/a n/a n/a
0 0 6 D DD DD DD D P D D
009 D D D D D D n/a n/a n/a n/a
0 1 1 D DD DD DD DD D
013 D D D D D D n/a n/a n/a n/a
014 D U D U D U n/a n/a n/a n/a
016 D D D D D D n/a n/a n/a n/a
0 1 7 D DD DD DD P D P D D
019 D D D X D DP DP DP D D
020 D D D D D D n/a n/a n/a n/a
No. taped 13 12 13 11 13 11 3 2 6 6
No. of interviews/total sought 13/13 12/13 13/13 11/13 13/13 12/13 6/6 6/6 6/6 6/6
Key:
D = completed data collection point by interview and taped
DI = completed data collection point by interview, but not taped
DP = completed data collection point postally (at patient/carer request due to holiday), but not taped
n/a = not applicable i.e. in fast-track group
X = data collection point missed due to carer burden (family illness and other caring commitments)
U = carer unavailable due to house moveBMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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Patient and carer missing data
For each patient and carer variable and outcome variable
results are given in terms of the feasibility findings (miss-
ing data and comments on acceptability) for patients and
for carers. Missed measurement points for patients and
carers were minimal. As noted above, one carer could not
be contacted at all due to a house move and one patient
died before t3 and was therefore lost to attrition. The
obtained and missing data points for the remaining 13
patients and 12 carers are given in Table 6.
For those completing the protocol Table 6 shows that
there were no missed patient measurement points and
only one missed carer measurement point: this was for a
t2 interview for a carer whose caring role to the trial
patient was secondary to another, primary, caring role:
this measurement point was abandoned due to acute ill-
ness in the carer's family.
Quantitative patient and carer missing data for individual
questionnaires and items is reported in Table 7 (Addi-
tional File 1).
Trial methodology
The fast-track trial methodology proved acceptable to the
patients, carers, referrers and BIS providers. No com-
plaints or negative comments were received from any par-
ticipants randomised to the waiting list group about their
period of waiting. The timings of the interviews (measure-
ment points) were manageable from a researcher perspec-
tive, fitted with the service provision and appeared
acceptable to respondents.
Patient and carer baseline and final interviews lasted
between an hour and an hour and a half (approximately);
other follow up interviews lasted between 30 minutes and
an hour (approximately). Patients were contacted by tele-
phone during the morning of each planned interview
before the researcher set out, to re-check the suitability of
the appointment in terms of the patients' health status
that day: this resulted in a small number of interviews
being re-scheduled.
Service model
In addition to these findings relating to the feasibility of
the trial there were findings relating to the feasibility of
the service model collected through interviews with the
BIS staff themselves. The service model for Phase II was an
eight-week intervention however it became clear that a
more focused intervention could be conducted over a
four-week period. This would have the added advantage
of reducing the waiting time for patients randomised to
the waiting list group to four-weeks in Phase III, so poten-
tially increasing acceptability still further.
Discussion
Response rate
Although based on a small sample size, this Phase II RCT
achieved a reasonably good response rate for a trial con-
ducted in palliative care that is worthy of further com-
ment. Possible reasons for this response rate include the
relationship between the research and clinical team, the
patient recruitment letter, the use of a fast-track design,
the patient group, and patient altruism. The relationship
between the research and clinical team was undeniably
strengthened by the research-culture of the clinical team,
in particular its desire to learn from the various phases of
the evaluation and remodel the service accordingly. The
evaluation was initiated by the lead clinician who
founded the service (SB) and who invited in academic col-
laboration. The service has been involved in every phase
of the evaluation but with all aspects of data collection
and much of the analysis being conducted independently
of it. This is similar to the participatory approach
described by Hopkinson et al (2005) [24]. The frequently
reported gate-keeping role of service providers [25-28] or
lack of support from clinical colleagues [8] was therefore
not an issue for this study.
A notable feature of the patient recruitment letter was
that, at the ethics committee's insistence, it was printed on
BIS's own clinical letterhead (which indicated it was part
of the palliative care team), as opposed to on the aca-
demic letterhead of the independent research team (i.e.
King's College London). This may have increased patients'
acceptance of the trial.
Palliative care patients, and their families, can be reluctant
to participate in trials with a traditional design, where
patients are randomised to an intervention or no interven-
tion [8]. The use of a fast-track design meant that all
patients had access to the intervention and, in addition,
those in the fast-track group had access to it earlier than
would normally be the case. Within the context of NHS
culture patients are familiar with waiting lists and often
expect to wait for a service: thus the short lead-in time to
receiving BIS for those randomised to the fast-track group
may have increased the response rate to this study.
Further the patient group targeted by this study may in
itself have had an impact on study recruitment. Services
for COPD patients are inconsistent and sporadic [13,29-
31], and access to palliative care is limited [32-34]. Thus
access to any service for these patients is likely to be desir-
able, and a novel service particularly so. This may have
been further compounded by an appreciation of research
focusing on a symptom that is distressing, yet not often
discussed openly, as highlighted in the earlier phases of
this research [13,14,35]. One Phase II patient describedBMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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the symptom of breathlessness, unlike pain, as 'not very
fashionable' (P006).
Low attrition & missing data rates
The study achieved a low attrition rate and low missing
data rate, again unusual for a palliative care RCT [8,10].
Using the same fast-track design Higginson et al (2008)
[10] had lower still attrition and missing data rates: they
suggested that the disease trajectory of the target group,
combined with the use of a fast-track design and highly
skilled interviewers were the likely explanations for their
success; the same reasons are likely to hold true for this
study. A similar study with patients with malignant dis-
ease may not achieve such relatively low rates. The small
sample size negates the possibility of exploring the rela-
tionship between patient characteristics and the response
rates, attrition or patterns of missing data.
Single-blinding
Our attempt at single-blinding was partially successful (6/
25 early unblinding rate). This was achieved with rela-
tively small effort on the part of the research, randomisa-
tion and clinical team. The effort on the part of
respondents is unknown, but data collection was carefully
designed to minimise this effort and maintain the quality
of the respondent-interviewer relationship: all data collec-
tion prior to formal unblinding (all of t2 and first half of
t3) was quantitative; formal unblinding occurred mid-t3
once all quantitative measures (including the primary
outcome measure) other than service use data had been
completed and before the qualitative interview; formal
unblinding consisted of opening a sealed envelope in
front of respondents, reading out the contents and asking
respondents to confirm whether they had or had not
received the service, it was therefore made clear that the
researcher was now formally (and appropriately)
unblinded and that they were free to report any contact
with BIS or any other service in the subsequent 'use of
services' questions and qualitative interview. Respondents
were not therefore expected to maintain blinding whilst
participating in qualitative interviews or answering ques-
tions about service use (of BIS or any other services). In
the view of the experienced interviewer this strategy did
not introduce distance between the respondent and inter-
viewer, indeed respondents appeared to be encouraged at
the 'scientific' nature of the study.
The source of the early unblinding was, in all cases, the
respondents; this occurred most often at t2 when patients
mentioned visits from named individuals. We recom-
mend that the content of interviews at unblinded meas-
urement points should be carefully considered when
designing blinded-trial protocols: there is a need to find a
balance between reducing the chances of accidental
unblinding and the collection of data that is of value and
that is blinded e.g. in the case of this study, primary out-
come measure data was collected at each interview whilst
the researcher was blinded but the collection of service use
data and qualitative data was deferred until after the for-
mal unblinding stage of the t3 interview.
Baseline and outcome measures
The majority of measures tested in the trial proved suita-
ble. Key exceptions were the WHO Performance Scale [16]
and the Schedule for the Evaluation of Individual Quality
of Life-Direct Weighting (SEIQoL-DW) [17]. The WHO
Performance Scale lacked specificity for advanced COPD
patients and will be replaced in Phase III by the Australia-
modified Karnosfsky Performance Status Scale (AKPS)
[36]. Based on the Karnofsky Performance Scale (KPS)
[37] and the community care based Thorne-modified KPS
(TKPS) [38], the AKPS accommodates any setting of care
and is considered more relevant to palliative care [36].
Despite the high completion rate on the SEIQoL-DW,
concerns about aspects of the process of administration
led the research team to question the validity of the results
obtained [39]. In Phase III quality of life will be assessed
using a combination of the EQ-5D [40] (a brief measure
of health status/health-related quality of life also required
for the cost-effectiveness analyses), the full Chronic Respi-
ratory Questionnaire [18] (Phase II used only the mastery
scale), and qualitative interviews (open questions on the
impact of breathlessness and the BIS on quality of life).
This in line with the recommendations of Guthrie et al
(2001) [41] and the 2005 MRC Clinical Trials Unit/Cicely
Saunders Foundation 'Improving Research Methodology
in Breathlessness' meeting [7].
Role of Phase II
Grande & Todd (2000) describe the need for feasibility
studies and careful piloting in order to carry out successful
RCTs in palliative care [8]. Conducting this Phase II RCT
provided crucial process and outcome data that has subse-
quently informed the robust design of Phase III: a single-
blinded fast-track pragmatic RCT of BIS versus standard
care for patients with any diagnosis. In addition, Phase II
has provided additional data to further refine the service
model of BIS prior to the commencement of Phase III.
This feasibility study focused on patients with COPD. It
seems reasonable, due to similarities in disease trajecto-
ries, to expect its findings (in terms of the feasibility and
acceptability of the methodology) to be generalisable to
patients with other non-malignant conditions with simi-
lar trajectories (e.g. cystic fibrosis) with intractable breath-
lessness who may be referred to BIS in Phase III. However,
generalisability to patients with breathlessness due to
malignancies or those non-malignant illnesses that followBMC Palliative Care 2009, 8:9 http://www.biomedcentral.com/1472-684X/8/9
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a malignant trajectory (e.g. interstitial lung disease) is
unknown.
While none of the individual components of this study
could be described as particularly novel (e.g. fast-track
methodology, single-blinding, secondary care interven-
tion delivered in the community, RCT in palliative care),
the combination is. Von Gunten (2005) highlights the
need for 'well-powered definitive studies of both existing
and new approaches in terminally ill patients with the
most common symptoms', including breathlessness [42].
Further, Bausewein et al (2007), reporting on an interna-
tional meeting on breathlessness, noted the need for fur-
ther examination of breathlessness intervention services
in order to elucidate which components work most effec-
tively in different conditions (e.g. malignant and non-
malignant) [43]. Phase II has provided key data for the
definitive Phase III RCT of BIS.
Conclusion
In conclusion, this Phase II RCT has provided valuable
information of the acceptability and feasibility of an RCT
of BIS for patients with COPD. It has shown that: single-
blinding is possible in a palliative care RCT and high-
lighted aspects of protocol design to reduce the unblind-
ing rate; fast-track trials appear acceptable for patients
with advanced COPD, their carers and referrers, as well as
the clinicians (intervention providers); high response
rates and low attrition can be achieved in palliative care
RCTs with non-malignant patients; and, that baseline and
outcome measures could be improved on. The trial has
also provided vital data for the sample size calculations
for Phase III (ClinicalTrials.gov NCT006-78405; NCRN
Portfolio Study No. 4829).
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